---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-013517"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2021-12-23T23:59:59+00:00"
generated_at: "2026-06-27T22:29:30.318262+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma regains Nasdaq compliance for independent director and audit committee rules

## Summary
- Received Nasdaq Staff letter on Dec 22, 2021 confirming compliance with Listing Rule 5605(b)(1).
- Prior non-compliance stemmed from Michael Breen's appointment as Executive Chairman on Nov 8, 2021.
- Nasdaq had notified the company of the deficiency on Nov 23, 2021.
- Compliance restored following resignation of director Anthony Cataldo effective Dec 15, 2021; matter closed.

## SEC filing metadata
- accession: 0001654954-21-013517
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2021-12-23T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000165495421013517/0001654954-21-013517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000165495421013517/gtbp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-013517
- JSON: https://secwatch.observer/filing/0001654954-21-013517.json
- Plain text: https://secwatch.observer/filing/0001654954-21-013517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.